AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Soluble Pd-1 Variants, Fusion Constructs, And Uses Thereof

Summary

The Subject Invention Provides Novel Soluble Pd-1 (Spd-1) Proteins, Nucleic Acids, And Fusion Constructs Thereof, For Enhancing Humoral And Cell-Mediated Immunity Of A Subject. Also Provided Are Therapeutic Compositions Comprising The Spd-1 Proteins, Nucleic Acids, And Fusion Constructs Of The Subject Invention. In A Preferred Embodiment, The Therapeutic Composition Is Formulated As A Vaccine Composition. Advantageously, The Spd-1 Proteins, Nucleic Acids, And Therapeutic Compositions Provide Protective Immunity Against Pathogenic Infection Including Hiv Infection. In Additon, The Subject Invention Can Be Used In The Prevention And/Or Treatment Of Tumor Or Cancer.

Supplementary Information

Patent Number: US9029315B2
Application Number: US13294306A
Inventor: Chen, Zhiwei | Zhou, Jingying
Priority Date: 11 Nov 2010
Priority Number: US9029315B2
Application Date: 11 Nov 2011
Publication Date: 12 May 2015
IPC Current: A01N006100 | A61K003800 | A61K003816 | A61K003921 | C07K0014005 | C07K0014705 | A61K003900
US Class: 514001 | 5140189 | 5140212 | 5360234 | 5360235
Assignee Applicant: The University of Hong Kong
Title: Soluble PD-1 variants, fusion constructs, and uses thereof
Usefulness: Soluble PD-1 variants, fusion constructs, and uses thereof
Summary: The sPD-1 protein is used in PD-1 fusion protein for preventing or treating pathogenic infection and/or tumor or cancer. The pathogenic infection is caused by pathogen chosen from human immunodeficiency virus (HIV), herpes simplex virus, respiratory syncytial virus, rhinovirus, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, hepatitis F virus, hepatitis G virus, oncovirus, human T-lymphotropic virus type I, influenza virus, bovine leukemia virus, Epstein-Barr virus, rotavirus, papillomavirus, pneumococcus, Streptococcus , Staphylococcus , Escherichia coli , cytomegalovirus, respiratory syncytial virus, parainfluenza virus, adenovirus, flavivirus, dengue virus, Mycobacterium tuberculosis , and Plasmodium falciparum (all claimed).
Novelty: New soluble programmed death 1 (PD-1) protein used in PD-1 fusion protein for preventing or treating pathogenic infection and/or tumor or cancer, comprises specific amino acid sequences

Industry

Disease Diagnostic/Treatment

Sub Group

HIV

Application No.

US13294306A

Country/Region

Hong Kong

For more information, please click Here